Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone908-947-3120
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$775.79 million
Profitability
Miscellaneous
Employees1,257
OptionableOptionable
Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions
What is Amneal Pharmaceuticals' stock symbol?
Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."
How were Amneal Pharmaceuticals' earnings last quarter?
Amneal Pharmaceuticals Inc (NYSE:AMRX) released its earnings results on Wednesday, November, 7th. The company reported $0.28 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.27 by $0.01. The firm earned $476.50 million during the quarter, compared to analysts' expectations of $486.01 million. Amneal Pharmaceuticals had a positive return on equity of 4.98% and a negative net margin of 36.54%. Amneal Pharmaceuticals's revenue was up 87.1% compared to the same quarter last year. View Amneal Pharmaceuticals' Earnings History.
When is Amneal Pharmaceuticals' next earnings date?
What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?
Amneal Pharmaceuticals updated its FY18 earnings guidance on Wednesday, November, 7th. The company provided EPS guidance of $0.90-0.92 for the period, compared to the Thomson Reuters consensus estimate of $0.95.
What price target have analysts set for AMRX?
10 brokerages have issued 1 year price objectives for Amneal Pharmaceuticals' stock. Their predictions range from $15.00 to $35.00. On average, they expect Amneal Pharmaceuticals' stock price to reach $21.75 in the next year. This suggests a possible upside of 75.1% from the stock's current price. View Analyst Price Targets for Amneal Pharmaceuticals.
What is the consensus analysts' recommendation for Amneal Pharmaceuticals?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amneal Pharmaceuticals.
What are Wall Street analysts saying about Amneal Pharmaceuticals stock?
Here are some recent quotes from research analysts about Amneal Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories Inc., is based in New Jersey, United States. " (1/14/2019)
- 2. Canaccord Genuity analysts commented, "We expect the deal to bring accretion starting in 2Q/19, which should help contribute to achieving the long-term goals that management set at the Impax/Amneal announcement, of double-digit revenue and EPS growth through 2020. In addition, we believe the deal is evidence of Amneal’s deal- making prowess that could result in further creative transactions moving forward. That said, as the core business continues to perform, we expect sentiment to improve on AMRX shares as the newco puts a number of quarters under its belt. We’re waiting on the sidelines as we watch the company continue to evolve; maintain HOLD. Deal consolidates branded and generic JSP levo products. The transaction gives Amneal access to JSP’s generic levothyroxine, an approximately $200 million run-rate product, in addition to the branded Unithroid Amneal already distributes for JSP." (8/20/2018)
- 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and 12-month price target of $35. EPS beat, Amneal lowered its 2018 financial guidance. Since the decrease was primarily driven by the timing of product opportunities, our investment thesis remains intact. We still believe that Amneal will be able to successfully grow from a mid-size generics company into a leading generics and specialty pharma company. Therefore, upward earnings revisions in 2019+ should drive the stock higher. These upward earnings revisions should come from: 1) operating margin expansion, 2) high-margin brand drug sales, and 3) strategic M&A, post the integration of Amneal." (8/9/2018)
- 4. Guggenheim analysts commented, "We were not including it in our prior estimates and are now increasing our revenue and adjusted EPS estimates." (5/18/2018)
Has Amneal Pharmaceuticals been receiving favorable news coverage?
Headlines about AMRX stock have been trending very positive on Monday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amneal Pharmaceuticals earned a daily sentiment score of 3.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are some of Amneal Pharmaceuticals' key competitors?
Some companies that are related to Amneal Pharmaceuticals include Ono Pharmaceutical (OPHLF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Genmab A/S (GNMSF), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Nektar Therapeutics (NKTR), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO) and Dr.Reddy's Laboratories (RDY).
Who are Amneal Pharmaceuticals' key executives?
Amneal Pharmaceuticals' management team includes the folowing people:
- Mr. Chirag K. Patel, Co-Founder & Co-Chairman (Age 51)
- Mr. Chintu Patel, Co-Founder & Co-Chairman (Age 46)
- Mr. Robert A. Stewart, Pres, CEO & Director (Age 50)
- Mr. Paul M. Bisaro, Exec. Chairman (Age 57)
- Mr. Bryan M. Reasons, Chief Financial Officer (Age 51)
Who are Amneal Pharmaceuticals' major shareholders?
Amneal Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.04%) and Virtu Financial LLC (0.01%). Company insiders that own Amneal Pharmaceuticals stock include Bryan M Reasons and Nikita Shah. View Institutional Ownership Trends for Amneal Pharmaceuticals.
Which major investors are selling Amneal Pharmaceuticals stock?
AMRX stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc.. Company insiders that have sold Amneal Pharmaceuticals company stock in the last year include Bryan M Reasons and Nikita Shah. View Insider Buying and Selling for Amneal Pharmaceuticals.
Which major investors are buying Amneal Pharmaceuticals stock?
How do I buy shares of Amneal Pharmaceuticals?
Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amneal Pharmaceuticals' stock price today?
One share of AMRX stock can currently be purchased for approximately $12.42.
How big of a company is Amneal Pharmaceuticals?
Amneal Pharmaceuticals has a market capitalization of $3.71 billion and generates $775.79 million in revenue each year. The company earns $-469,280,000.00 in net income (profit) each year or $0.63 on an earnings per share basis. Amneal Pharmaceuticals employs 1,257 workers across the globe.
What is Amneal Pharmaceuticals' official website?
How can I contact Amneal Pharmaceuticals?
Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]
MarketBeat Community Rating for Amneal Pharmaceuticals (NYSE AMRX)
MarketBeat's community ratings are surveys of what our community members think about Amneal Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
